Trial Profile
Immunogenicity and Safety of Gardasil (V501) Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Consistency Lots for 16- to 23-Year-Old Women With and Additional Immunogenicity Bridge to the Monovalent HPV 16 Vaccine Pilot Manufacturing Lot Study-The F.U.T.U.R.E. Study (Females United to Unilaterally Reduce Endo/Ectocervical Disease)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary) ; Hepatitis B vaccine recombinant; Human papillomavirus vaccine
- Indications Cervical cancer; Genital warts; Human papillomavirus infections
- Focus Adverse reactions; Pharmacodynamics
- Acronyms The F.U.T.U.R.E. Study
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 30 Mar 2017 New trial record